GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (NAS:ATRA) » Definitions » Operating Margin %

Atara Biotherapeutics (Atara Biotherapeutics) Operating Margin %

: -1,410.21% (As of Dec. 2023)
View and export this data going back to 2014. Start your Free Trial

Operating Margin % is calculated as Operating Income divided by its Revenue. Atara Biotherapeutics's Operating Income for the three months ended in Dec. 2023 was $-59.96 Mil. Atara Biotherapeutics's Revenue for the three months ended in Dec. 2023 was $4.25 Mil. Therefore, Atara Biotherapeutics's Operating Margin % for the quarter that ended in Dec. 2023 was -1,410.21%.

The historical rank and industry rank for Atara Biotherapeutics's Operating Margin % or its related term are showing as below:

ATRA' s Operating Margin % Range Over the Past 10 Years
Min: -3219.48   Med: -1673.85   Max: -441.25
Current: -3219.48


ATRA's Operating Margin % is ranked worse than
84.02% of 1026 companies
in the Biotechnology industry
Industry Median: -178.545 vs ATRA: -3219.48

Atara Biotherapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Atara Biotherapeutics's Operating Income for the three months ended in Dec. 2023 was $-59.96 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-276.01 Mil.


Atara Biotherapeutics Operating Margin % Historical Data

The historical data trend for Atara Biotherapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => - [4] => - [5] => - [6] => - [7] => -1,673.85 [8] => -441.25 [9] => -3,219.48 )
Atara Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -1,673.85 -441.25 -3,219.48

Atara Biotherapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34,180.54 -6,118.92 -7,462.28 -3,255.94 -1,410.21

Competitive Comparison

For the Biotechnology subindustry, Atara Biotherapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atara Biotherapeutics Operating Margin % Distribution

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Operating Margin % falls into.



Atara Biotherapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Atara Biotherapeutics's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-276.006 / 8.573
=-3,219.48 %

Atara Biotherapeutics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-59.962 / 4.252
=-1,410.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Atara Biotherapeutics  (NAS:ATRA) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Atara Biotherapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Atara Biotherapeutics (Atara Biotherapeutics) Business Description

Traded in Other Exchanges
Address
2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
Executives
Jill Henrich officer: EVP, Global Head RA & Quality 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Pascal Touchon director, officer: President and CEO C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD SUITE 900, SOUTH SAN FRANCISCO CA 94080
Amar Murugan officer: SVP, GC & Secretary C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD,SUITE 900, SOUTH SAN FRANCISCO CA 94080
Eric J Hyllengren officer: SVP, CFO 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Anhco Nguyen officer: EVP, Chief Sci. & Tech Officer 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Manher Joshi officer: EVP, Chief Medical Officer 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Eric Dobmeier director C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
William K Heiden director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Charlene A. Banard officer: EVP, Chief Technical Officer C/O APPLIED MOLECULAR TRANSPORT INC., 450 EAST JAMIE COURT, SOUTH SAN FRANCISCO CA 94080
Jakob Dupont officer: EVP, Head of R&D C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Utpal Koppikar officer: Chief Financial Officer C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO CA 94080
Ameet Mallik director C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Kristin Yarema officer: Chief Commercial Officer C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO CA 94080
Joe Newell officer: Chief Tech. Operations Officer C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO CA 94080